Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities.
One hundred forty patients affected by high risk or locally advanced melanoma of the extremities were submitted to hyperthermic perfusion in extracorporeal circulation at the National Cancer Institute of Milan, Italy. Using adequate temperature and drug dosage, we increased survival of stage IIIA patients from 8-15% to 51% and stage IIIAB patients from 7-8% to 35%, and good local control was achieved in stage IV patients. A comparison was made with 297 patients with similar disease treated in a previous period in this institute with conventional therapies such as surgery with or without chemotherapy. In stage IIIA patients we obtained 51% overall survival at 5 years in perfused cases, whereas survival in the series with conventional treatment reached 16%. Similarly, in stage IIIAB patients we observed 34% (perfused) versus 16% (conventional treatment) survival. There are still no data available for high-risk stage I, in which perfusion is employed as an adjuvant treatment.
Santinami
M
M
Surgical Oncology B, Istituto Nazionale Tumori, Milano, Italy.
Belli
F
F
Cascinelli
N
N
Rovini
D
D
Vaglini
M
M
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use; D005112:Extracorporeal Circulation; D005121:Extremities; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D008545:Melanoma / Q000473:pathology / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage / Q000627:therapeutic use; D009367:Neoplasm Staging; D012307:Risk Factors; D013997:Time Factors
D000970:Antineoplastic Agents; D003606:Dacarbazine; D002945:Cisplatin; D008558:Melphalan